J. Hauptman

Publications31
h-index18
Citations5,568
Highly Influential Citations214
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Reaven
  • 868 Publications • 78,109 Citations
  • W. Willett
  • 2,301 Publications • 347,034 Citations
  • G. Colditz
  • 1,606 Publications • 226,043 Citations
  • R. Wing
  • 738 Publications • 61,338 Citations
  • Publications
  • Influence
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
OBJECTIVE It is well established that the risk of developing type 2 diabetes is closely linked to the presence and duration of overweight and obesity. A reduction in the incidence of type 2 diabetes… Expand
  • 1,599
  • 66
  • PDF
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
CONTEXT Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. OBJECTIVE To test the… Expand
  • 858
  • 32
Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
OBJECTIVE Obesity is an important risk factor for type 2 diabetes. Weight loss in patients with type 2 diabetes is associated with improved glycemic control and reduced cardiovascular disease risk… Expand
  • 619
  • 22
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals. “Twincretins”: Two Is… Expand
  • 316
  • 19
  • PDF
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
CONTEXT The prevalence of overweight and obesity in children and adolescents is increasing rapidly. In this population, behavioral therapy alone has had limited success in providing meaningful,… Expand
  • 449
  • 17
  • PDF
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
BACKGROUND Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment. OBJECTIVE This multicenter, double-blind, placebo-controlled study was designed to test the… Expand
  • 288
  • 16
  • PDF
Orlistat in the long-term treatment of obesity in primary care settings.
OBJECTIVE To evaluate the long-term efficacy and tolerability within primary care settings of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity. DESIGN Randomized,… Expand
  • 322
  • 14
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
BACKGROUND Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose… Expand
  • 324
  • 10
  • PDF
Retrospective population‐based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
Orlistat, an inhibitor of gastrointestinal lipases, limits the absorption of ingested fat and could become a potential treatment for obesity. This analysis was performed to elucidate the relationship… Expand
  • 238
  • 6
Obesity: Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial
Background: Lifestyle measures are considered the first line of therapy for treating overweight individuals, but many are unable to achieve a meaningful weight loss. Objective: To determine the… Expand
  • 42
  • 3
...
1
2
3
4
...